AptarGroup Beats As Sales Reaccelerate, But Earnings Still Shrink And Beauty Remains The Weak Link

AptarGroup delivered the top-line inflection investors had been waiting for, though not yet the earnings growth. Third-quarter adjusted EPS of $1.52 beat the $1.46 consensus by 4.1% and landed at the upper end of management's $1.45-$1.53 guidance range. Revenue of $1.019 billion topped expectations by 4.4% and grew 6.0% year over year. Earnings still fell 6.2% from a year ago. That gap is the central tension of the quarter: demand is clearly improving across all three segments, but margins, taxes and corporate costs are still absorbing the benefit.

The quality of the beat deserves scrutiny. Core sales rose 5%, a sharp acceleration from 1% in Q2 and flat results in Q1. Gross margin, however, fell 120 basis points year over year. Consolidated adjusted EBITDA margin slipped to 21.3% from 23.2%, and adjusted EBITDA declined in dollar terms to $217 million from $223 million despite $58 million of additional sales. Below the line, the picture was similar:

• Adjusted corporate expense widened to roughly $21 million from $13 million, which management tied partly to the CEO transition.
• The adjusted tax rate rose to 23.4% from 20.8%.
• Interest expense increased.

A 2.5 million reduction in diluted share count cushioned the decline. On a GAAP basis, EPS collapsed to $0.51 from $1.92, driven by a $0.94-per-share charge from deconsolidating the Russian subsidiary after a government decree. That charge included roughly $30 million of cash that is now effectively gone. It is excluded from adjusted results, but it is a real loss of value, not merely an accounting artifact.

The call made a more encouraging case on trajectory than the year-over-year comparisons suggest.

• **Pharma:** Core sales rose only 1%, but grew 8% excluding emergency medicine (naloxone) destocking, the second straight quarter at that pace. Consumer healthcare grew 13% and injectables 9%. Pharma's adjusted EBITDA margin rebounded to 36.4% from 33.6% in Q2 and 33.3% in Q1, and consolidated margin improved sequentially for a second quarter.
• **Closures:** This was the standout, with core sales up 11% versus 4% in Q2 and beverage up 19% on the new dispensing closure technology.
• **Beauty:** Core growth jumped to 8% from 1%, though roughly half came from cost pass-throughs. Pass-throughs also diluted margins in both Beauty and Closures.

Not everything moved the right way. Prescription growth excluding emergency medicine eased to 6% from 8%. Beauty's margin slipped to 11.4% from 12.2% in Q2, despite earlier expectations that the pass-through lag would resolve. New CEO Gael Touya was candid that North American Beauty has lost share with some customers, is subscale in indie brands, and will not see a quick or linear fix. Bears have legitimate ammunition there.

The forward setup is where the story improves. Management confirmed that the naloxone destock laps in Q4. It guided Q4 adjusted EPS to $1.39-$1.47, versus $1.22 a year ago, which management frames as roughly 17% constant-currency growth; Earnings Whispers characterizes the guide as above estimates. If delivered, that would end a streak of year-over-year EPS declines (-8% in Q1, -15% in Q2, -6% in Q3). However, the post-destock naloxone baseline will not be visible until Q1 2027, and management expects only GDP-like growth from there.

The pipeline disclosures were also notably richer than usual:

• a system-level injectables collaboration with Stevanato;
• the Pulmotree/Colibri non-propellant inhaler acquisition;
• research partnerships with Mass General and Macquarie;
• a new elastomer standard aimed at biologics and GLP-1s;
• an Rx-to-OTC acne switch using an Aptar device.

The dividend was raised 4%, and year-to-date free cash flow reached $198 million. Cash nonetheless fell to $204 million from $402 million at year-end as the company paid down debt and repurchased shares.

Investors were not leaning bullish into the print. Earnings Whispers sentiment slipped from slightly positive (0.04) to slightly negative (-0.09), a modest shift rather than a capitulation. Shares at $130.64 were down 5.0% from the open after the July report but still about 3% above the 200-day moving average of $126.88. The stock has been drifting lower without breaking down. Trend readings are mixed, with price trend negative while AVWAP remains positive.

The bottom line is that Aptar's quarter marked a genuine operating turn: sales are reaccelerating, Pharma margins have recovered, and Q4 guidance points to the first year-over-year earnings growth of 2026. The beat came with persistent gross-margin pressure, a structurally challenged North American Beauty business, elevated corporate costs, and a Russia write-off. Q4 execution against the destock lap, along with any evidence that the new CEO can stabilize Beauty, will determine whether the improving trajectory translates into durable earnings growth.

Read our earnings preview for AptarGroup, Inc.: https://www.earningswhispers.com/article/ATR/21166

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.